Cargando…
Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266676/ https://www.ncbi.nlm.nih.gov/pubmed/35806328 http://dx.doi.org/10.3390/ijms23137325 |
_version_ | 1784743526623346688 |
---|---|
author | Kang, Byeong Hoon Lee, Heung Kyu |
author_facet | Kang, Byeong Hoon Lee, Heung Kyu |
author_sort | Kang, Byeong Hoon |
collection | PubMed |
description | Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors. |
format | Online Article Text |
id | pubmed-9266676 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92666762022-07-09 Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors Kang, Byeong Hoon Lee, Heung Kyu Int J Mol Sci Review Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors. MDPI 2022-06-30 /pmc/articles/PMC9266676/ /pubmed/35806328 http://dx.doi.org/10.3390/ijms23137325 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kang, Byeong Hoon Lee, Heung Kyu Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title_full | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title_fullStr | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title_full_unstemmed | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title_short | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors |
title_sort | dendritic cell-based immunotherapy in hot and cold tumors |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266676/ https://www.ncbi.nlm.nih.gov/pubmed/35806328 http://dx.doi.org/10.3390/ijms23137325 |
work_keys_str_mv | AT kangbyeonghoon dendriticcellbasedimmunotherapyinhotandcoldtumors AT leeheungkyu dendriticcellbasedimmunotherapyinhotandcoldtumors |